NCT06101043

Brief Summary

The da Vinci robotic system was developed to improve both operative maneuverability (through multi-articulated instruments) and the surgical view (via a three-dimensional camera). Although the system has many advantages, skin incision, wide flap dissection, and pneumatic/mechanical retraction remain essential, but cause postoperative pain and slower recovery. Previous studies found that pectoralis fascial blocks were easy to establish; local anesthetics are injected between two adjacent myofascial layers under ultrasound guidance, providing the surgeon with a clear image. Analgesic efficacy has been validated during robotic thyroidectomy in our institution. The pain outcomes were comparable between the groups, but there were fewer complications in the PECS II group. The investigators investigated whether this block can reduce postoperative pain during wide flap dissection for single-port robot-assisted transaxillary thyroidectomy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
76

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2024

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 19, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 25, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

January 4, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 28, 2024

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

January 5, 2024

Status Verified

January 1, 2024

Enrollment Period

9 months

First QC Date

October 19, 2023

Last Update Submit

January 3, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Analgesic efficacy

    Visual analog scale from 0 (minimum) to 10 (maximum)

    the day after surgery

Secondary Outcomes (1)

  • Quality of postoperative surgery course

    the day after surgery

Study Arms (2)

PECS II block group

EXPERIMENTAL
Procedure: Pectoral nerve block

No PECS II block group

NO INTERVENTION

Interventions

An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).

PECS II block group

Eligibility Criteria

Age19 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients aged 19 to 60 years who are scheduled to undergo single-port robot thyroidectomy (lobectomy or total thyroidectomy)
  • Patients with cancer stages T1 or T2 (less than 4 cm without invasion of surrounding tissue) when thyroid cancer is suspected in the preoperative examination
  • Patients with nodules with a maximum length of less than 4 cm based on ultrasonography if thyroid cancer is not suspected in the preoperative examination
  • Patients with a BMI greater than or equal to 18.5 and less than 30.0.

You may not qualify if:

  • Patients requiring lateral cervical lymph node dissection
  • pregnant women
  • Uncontrolled diabetes
  • Chronic kidney failure
  • Patients with previous neck surgery
  • Patients with Graves' disease
  • People with chronic alcoholism
  • Patients with vocal cord paralysis before surgery
  • Severe obese patients with a body mass index \>35 kg/m2
  • Patients participating in another clinical trial within 30 days
  • Patients who expect that it will be difficult for medical staff to fill out the questionnaire on their own
  • Patients whose medical staff determines that participation in the study is difficult due to other underlying diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Central Study Contacts

Min Suk Chae, MD, PhD

CONTACT

Kwangsoon Kim, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

October 19, 2023

First Posted

October 25, 2023

Study Start

January 4, 2024

Primary Completion

September 28, 2024

Study Completion

September 30, 2024

Last Updated

January 5, 2024

Record last verified: 2024-01